Next Article in Journal
Low-Frequency Raman Spectroscopy: An Exceptional Tool for Exploring Metastability Driven States Induced by Dehydration
Previous Article in Journal
Exploring the Microfluidic Production of Biomimetic Hybrid Nanoparticles and Their Pharmaceutical Applications
Previous Article in Special Issue
Cationic Polymers as Transfection Reagents for Nucleic Acid Delivery
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Editorial for Special Issue: Advanced Technologies for Developing the State-of-the-Art Nanomedicines

1
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Multi-Disciplinary Research Division, Institute of High Energy Physics and University of Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences (CAS), Beijing 100049, China
2
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing 100730, China
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2023, 15(7), 1954; https://doi.org/10.3390/pharmaceutics15071954
Submission received: 6 July 2023 / Accepted: 13 July 2023 / Published: 15 July 2023
This Special Issue aims to introduce advanced technologies that promote the development of nanomedicines. In recent decades, nanotechnology has been widely applied in various areas of modern medicines, and has provided significant help in developing safe, effective, and precise drug therapies. The Special Issue collects 10 articles that explore different advanced technologies for developing state-of-the-art nanomedicines, including nucleic acid therapy, myocardial infarction, and cancer treatments. The aim of this issue is to provide a review of recent developments and encourage continued progress in this field.
The COVID-19 pandemic has sparked a huge increase in research into nucleic acid therapy, which has garnered significant attention as a potential treatment and preventive option. Nucleic acid therapy can achieve long-lasting and curative effects through gene enhancement, inhibition, editing, and other methods. However, to be effective, it requires delivery systems, since naked nucleic acids cannot enter cells effectively. This Special Issue includes a review article on nucleic acid delivery, which highlights cationic polymers as a promising delivery system due to the ease of synthesis, modification, and structural control [1]. In addition, because of the unique advantage of RNA in nucleic acid therapy, two articles on RNA delivery are also included. One article addresses the challenge of treating chronic hepatitis B, a major cause of liver diseases such as hepatocellular carcinoma (HCC). The authors show that co-delivering siRNA targeting HBV X protein (HBx) and a plasmid encoding interleukin-12 (pIL-12) can effectively inhibit virus replication, reactivate the immune system, and slow down the development of HCC [2]. This work holds great promise for improving treatment options for patients with chronic hepatitis B. Another article uses all-atom MD simulations to investigate the thermal stability of three-way junction-packaged RNA (3WJ-pRNA). The authors discover that Mg2+ ions can regulate the thermal stability of 3WJ-pRNA, which could be valuable in developing controllable RNA nanogranule drug delivery platforms [3]. These findings are critical for designing efficient and effective RNA delivery systems.
Small-molecule medicines have been widely used in various diseases. The nanoformulation of these medicines can fundamentally alter their in vivo bioavailability. In the treatment of myocardial infarction, nanocarriers have shown potential advantage. A review article in this issue summarizes important principles and developments in the field, focusing on the nanocarriers with ligand-based or cell mimicry-based targeting and discussing the current limitations and future directions [4]. In addition, this issue includes three papers related to cancer treatments, where nanocarriers have played an essential role. These include (1) a promising nanobiophotonic theranostic (ICG-MB) for cancer phototherapy, which is simple and biocompatible [5]. When stimulated by near-infrared laser irradiation, it exhibits enhanced photothermal conversion and singlet oxygen generation to ablate cancer cells. This cancer phototherapy candidate is self-assembled from two FDA-approved dyes without additional additives. (2) A high drug-loaded nanocarrier crystalline micelle is produced using a diblock copolymer, poly(oligo ethyleneglycol) methacrylate-b-poly(styrene-co-4-formylphenyl methacrylate) (PPP) as a stabilizer. The micelle exhibits excellent colloidal stability, controllable drug release, and prolonged circulation properties. It can induce high accumulation in tumor tissues even after repeated administration, achieving continuous antitumor efficacy [6]. (3) The modulation of M1 extracellular vesicles (MM1-EVs) loaded with doxorubicin enhances the antitumor effect of chemotherapy in a metastatic cancer mouse model [7]. MM1-EVs reduce the size and metastasis of primary tumors, decrease the expression of M2-TAMs, and enhance tumor apoptosis.
The physio-chemo properties of nanocarriers are crucial factors affecting the efficacy of drug delivery, and optimizing their properties can further enhance their prospects in the medical fields. Two research articles in this Special Issue focus on this concept. The first article seeks the optimal properties of nanoparticles (NPs) in mediating improved in vivo responses. The authors evaluated NPs prepared from five materials of three sizes and three concentrations in a cell barrier model. They found that ZnO NPs cause significant alterations to cell viability across all three cell lines tested, while NPs with a physiological-based zeta potential of −12 mV result in good cell barrier penetration without considerable changes in cell viability [8]. Another article describes the synthesis of aliphatic polyanhydrides with various hydrophobic segments, controllable molecular weights, low polydispersity, and potential for use as drug carriers. The authors synthesized a series of polyanhydrides using suberic, azelaic, sebacic, and dodecanedioic acids and achieved reduced polydispersity [9]. The molecular weights of the synthesized polyanhydrides are highly controllable and depend on the degree of activation of the dicarboxylic acid monomers, i.e., the amount of acetic anhydride used during synthesis. Furthermore, unlike traditional methods of optimizing material properties, choosing the appropriate stereoisomer can significantly impact drug efficacy and adverse reactions. Therefore, this Special Issue also includes a review article which highlights the influence of nanoparticle chirality on the interactions with biological systems and introduces the chiral materials used in nanomaterials [10].
In conclusion, this Special Issue highlights the significant progress and promising outlook for nanomedicines in various medical fields. The articles cover several topics, including nucleic acid therapy, myocardial infarction, cancer treatment, and the optimization of nanocarrier properties. These studies provide valuable insights into the development of efficient and effective medical treatments using nanotechnology. By exploring new approaches and avenues for developing novel nanoparticle-based therapies, researchers have demonstrated these materials’ vast and exciting potentials in modern medicines. With insights from these articles, we can expect continued advancements and breakthroughs in the development of efficient and effective medical treatments using nanotechnology in the future.

Author Contributions

Conceptualization, J.C.; writing—original draft preparation, Y.H.; writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China, grant number 11875269 and 21574136; Guangdong Basic and Applied Basic Research Foundation, grant number 2022A1515140073; and the National High Level Hospital Clinical Research Funding, grant number 2022-PUMCH-E-004.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Cai, X.; Dou, R.; Guo, C.; Tang, J.; Li, X.; Chen, J.; Zhang, J. Cationic Polymers as Transfection Reagents for Nucleic Acid Delivery. Pharmaceutics 2023, 15, 1502. [Google Scholar] [CrossRef] [PubMed]
  2. Mu, Y.; Ren, X.H.; Han, D.; Guan, Y.Y.; Liu, P.L.; Cheng, S.X.; Liu, H. Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity. Pharmaceutics 2022, 14, 1439. [Google Scholar] [CrossRef] [PubMed]
  3. Chen, L.; Li, J. Mg2+ Ions Regulating 3WJ-PRNA to Construct Controllable RNA Nanoparticle Drug Delivery Platforms. Pharmaceutics 2022, 14, 1413. [Google Scholar] [CrossRef] [PubMed]
  4. George, T.A.; Hsu, C.C.; Meeson, A.; Lundy, D.J. Nanocarrier-Based Targeted Therapies for Myocardial Infarction. Pharmaceutics 2022, 14, 930. [Google Scholar] [CrossRef] [PubMed]
  5. Huang, M.; Xu, C.; Yang, S.; Zhang, Z.; Wei, Z.; Wu, M.; Xue, F. Vehicle-Free Nanotheranostic Self-Assembled from Clinically Approved Dyes for Cancer Fluorescence Imaging and Photothermal/Photodynamic Combinational Therapy. Pharmaceutics 2022, 14, 1074. [Google Scholar] [CrossRef] [PubMed]
  6. Liang, H.; Zou, F.; Fu, L.; Liu, Q.; Wang, B.; Liang, X.; Liu, J.; Liu, Q. PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML). Pharmaceutics 2022, 14, 1662. [Google Scholar] [CrossRef] [PubMed]
  7. Jorquera-Cordero, C.; Lara, P.; Cruz, L.J.; Schomann, T.; van Hofslot, A.; de Carvalho, T.G.; Guedes, P.; Creemers, L.; Koning, R.I.; Chan, A.B.; et al. Extracellular Vesicles from M1-Polarized Macrophages Combined with Hyaluronic Acid and a beta-Blocker Potentiate Doxorubicin’s Antitumor Activity by Downregulating Tumor-Associated Macrophages in Breast Cancer. Pharmaceutics 2022, 14, 1068. [Google Scholar] [CrossRef] [PubMed]
  8. Ross, A.M.; Cahalane, R.M.; Walsh, D.R.; Grabrucker, A.M.; Marcar, L.; Mulvihill, J.J.E. Identification of Nanoparticle Properties for Optimal Drug Delivery across a Physiological Cell Barrier. Pharmaceutics 2023, 15, 200. [Google Scholar] [CrossRef] [PubMed]
  9. Ghosh, R.; Arun, Y.; Siman, P.; Domb, A.J. Synthesis of Aliphatic Polyanhydrides with Controllable and Reproducible Molecular Weight. Pharmaceutics 2022, 14, 1403. [Google Scholar] [CrossRef] [PubMed]
  10. Jung, W.; Kwon, J.; Cho, W.; Yeom, J. Chiral Biomaterials for Nanomedicines: From Molecules to Supraparticles. Pharmaceutics 2022, 14, 1951. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Hu, Y.; Chen, J. Editorial for Special Issue: Advanced Technologies for Developing the State-of-the-Art Nanomedicines. Pharmaceutics 2023, 15, 1954. https://doi.org/10.3390/pharmaceutics15071954

AMA Style

Hu Y, Chen J. Editorial for Special Issue: Advanced Technologies for Developing the State-of-the-Art Nanomedicines. Pharmaceutics. 2023; 15(7):1954. https://doi.org/10.3390/pharmaceutics15071954

Chicago/Turabian Style

Hu, Yi, and Jun Chen. 2023. "Editorial for Special Issue: Advanced Technologies for Developing the State-of-the-Art Nanomedicines" Pharmaceutics 15, no. 7: 1954. https://doi.org/10.3390/pharmaceutics15071954

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop